C&G Editor in Chief, Erin Harris

1. Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More 6/24/2025

   During this month’s Cell and Gene Live, Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More, expert panelists Francesca Barone, M.D., Ph.D., CSO at Candel Therapeutics and Karen Kozarsky, Ph.D., President of Vector BioPartners shared their perspectives on current challenges, technological innovations, and future directions in gene therapy vector development and application.

2. Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham 6/23/2025

   The RISE framework — focused on Resource sharing, Interdisciplinary collaboration, Sustainable funding, and Educational outreach — is helping academic medical centers such as Mass General Brigham overcome translational barriers in cell and gene therapy development and bring promising therapies closer to clinical application.

3. The Promise Of Focused Ultrasound For AAV Gene Therapy Delivery 6/11/2025

   Dr. Bernie Owusu-Yaw, a research fellow at Brigham and Women’s Hospital and Harvard Medical School, is pioneering a promising gene therapy approach that combines focused ultrasound with novel AAV capsids to safely and effectively deliver therapeutics across the blood-brain barrier, offering new hope for treating challenging neurodegenerative diseases.

4. Unlocking The Potential Of iPSC Therapies In Regenerative Medicine 5/21/2025

   In a recent Cell & Gene Live, leaders from Mayo Clinic and Astellas discussed the transformative potential of iPSC therapies in regenerative medicine, highlighting regulatory alignment and manufacturing innovation to realize their full impact.

5. Ferring Builds A Global Gene Therapy Manufacturing Network Around ADSTILADRIN 5/16/2025

   Ferring Pharmaceuticals has built a global manufacturing and support network around its flagship gene therapy, ADSTILADRIN, enabling scalable production, provider education, patient access, and real-world data collection to ensure sustainable and widespread adoption.

6. Atsena Therapeutics Advances Gene Therapy For XLRS 5/13/2025

   Atsena Therapeutics exemplifies the field’s growing shift toward non-oncology indications with its targeted gene therapy for X-linked retinoschisis, a rare inherited retinal disorder with no approved treatments.

7. Navigating CGT Biotech's Financial Headwinds And The Path Forward 4/24/2025

   Dr. Ali Pashazadeh, Founder of Treehill Partners shares how CGT companies can navigate today’s biotech downturn by embracing integrated strategies, disciplined capital use, and bold leadership willing to rethink traditional models across innovation, manufacturing, and commercialization.

8. How Cynata Therapeutics is Unlocking the Power of iPSCs to Transform Regenerative Medicine 4/11/2025

   Cynata Therapeutics is pioneering a scalable, iPSC-based platform to produce consistent, high-quality MSCs that are showing strong clinical promise across multiple indications, including GvHD, diabetic foot ulcers, and osteoarthritis.

9. Emerging Technologies For Cell Therapy Manufacturing 4/7/2025

   This summary of the Cell & Gene Live, Emerging Technologies in Cell Therapy Manufacturing, explains why automation, robotics, AI, and digital tools offer a clear path to scalable, efficient, and patient-centric manufacturing.

10. Collaboration Leads To CGT Progress At Astellas' West Coast Innovation Center 3/13/2025

    Yoshi Shitaka, outgoing CSO and Richard Wilson, SVP, Primary Focus Lead (Genetic Regulation) at Astellas share how the company's West Coast Innovation Center serves as a central hub for AI, digital transformation, and more.